DDA potentiates Ara-C cytotoxicity in AML cell lines and AML from... | Download Scientific Diagram
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
Ara-C metabolism. Ara-C: Cytarabine; Ara-CDP: Ara-C diphosphate;... | Download Scientific Diagram
Anti-leukemia effects of Ara-C@HFn and free Ara-C in AML mouse models.... | Download Scientific Diagram
Sequential Treatment with Cytarabine and Decitabine Has an Increased Anti-Leukemia Effect Compared to Cytarabine Alone in Xenograft Models of Childhood Acute Myeloid Leukemia | PLOS ONE
Cytarabine Dose for Acute Myeloid Leukemia | NEJM
Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death | BMC Cancer | Full Text
Enhanced cytarabine-induced killing in OGG1-deficient acute myeloid leukemia cells | PNAS
Combination strategies to promote sensitivity to cytarabine-induced replication stress in acute myeloid leukemia with and without DNMT3A mutations - Experimental Hematology
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
Stabilization of SAMHD1 by NONO is crucial for Ara-C resistance in AML | Cell Death & Disease
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), acute lymphocytic leukemia (AL Stock Vector Image & Art - Alamy
Enhanced sensitivity to glucocorticoids in cytarabine-resistant AML | Leukemia
Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier | Journal of Nanobiotechnology | Full Text
Mathematical Models for the Influence of Cytarabine on White Blood Cell Dynamics in Acute Myeloid Leukemia | bioRxiv
SNP analyses in cytarabine metabolizing enzymes in AML patients and their impact on treatment response and patient survival: identification of CDA SNP C-451T as an independent prognostic parameter for survival | Leukemia
Ribonucleotide reductase inhibitors suppress SAMHD1 ara‐CTPase activity enhancing cytarabine efficacy | EMBO Molecular Medicine
Cancers | Free Full-Text | Dendrogenin A Synergizes with Cytarabine to Kill Acute Myeloid Leukemia Cells In Vitro and In Vivo
Cancers | Free Full-Text | Response and Toxicity to Cytarabine Therapy in Leukemia and Lymphoma: From Dose Puzzle to Pharmacogenomic Biomarkers
Curcumin sensitizes response to cytarabine in acute myeloid leukemia by regulating intestinal microbiota | Cancer Chemotherapy and Pharmacology
![PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/e1ff2ef8f89b7329a74a5a2ac322bba45bc00394/2-Table1-1.png "PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar")
PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar
Molecules | Free Full-Text | Exploring the Antitumor Mechanism of High-Dose Cytarabine through the Metabolic Perturbations of Ribonucleotide and Deoxyribonucleotide in Human Promyelocytic Leukemia HL-60 Cells
Phase I and pharmacokinetic study of elacytarabine, a novel 5′-elaidic acid derivative of cytarabine, in adults with refractory hematological malignancies | Leukemia
A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model - ScienceDirect
IJMS | Free Full-Text | Inhibitors of Chemoresistance Pathways in Combination with Ara-C to Overcome Multidrug Resistance in AML. A Mini Review
Cytarabine (cytosine arabinoside, Ara-C) chemotherapy drug molecule. Used in treatment of acute myeloid leukemia (AML), etc Stock Photo - Alamy
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia | Nature Communications
IJMS | Free Full-Text | Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
